Table 1:

Participant demographics

No.	Age (yr)	Sex, Ethnicity	Side	Years since Onset	Prior Therapy	Symptoms	SRT/SDS^{^a}
No.	Age (yr)	Sex, Ethnicity	Side	Years since Onset	Prior Therapy	Symptoms	Right	Left
1	62	Female	Left	6	HCTZ	∼2 Vertigo episodes/year	20 dB	90 dB
						∼2 Vertigo episodes/year	96% at 60 dB	4% at 100 dB
2	45	Male	Right	3	HCTZ, oral steroids	Waxing/waning roaring tinnitus, occasional vertigo	15 dB	5 dB
						Waxing/waning roaring tinnitus, occasional vertigo	96% at 75 dB	100% at 45 dB
3	55	Male	Right	1	HCTZ	Tinnitus ×1 year,	15 dB	20 dB
						episodic vertigo ×2 mo	96% at 55 dB	96% at 80 dB
4	63	Female	Right	>10	Bilateral IT steroid injection, oral steroid, HCTZ	8 Vertigo attacks within 2 mo	65 dB	25 dB
					Bilateral IT steroid injection, oral steroid, HCTZ	8 Vertigo attacks within 2 mo	56% at 80 dB	96% at 50 dB
5	53	Female	Left	>10	Endolymphatic shunt, IT gentamicin ×9, IT steroids, gent/dex impregnated Gelfoam^{^b} sponge in round window niche	Tinnitus and pressure	10 dB	30 dB
							96% at 45 dB	92% at 65 dB
6	35	Female	Right	3	HCTZ	Episodic vertigo within prior 2 weeks	65 dB	10 dB
						Episodic vertigo within prior 2 weeks	44% at 80 dB	96% at 50 dB

Note:—HCTZ indicates hydrochlorothiazide; SRT, speech reception threshold; SDS, speech discrimination score (%) at supra-SRT level (decibel); gent/dex, gentamicin/dexamethasone.
↵a Normal = Less than 25, mild = 26–40, moderate = 41–55, moderate/severe = 56–70, severe = 71–90, profound hearing loss >90.
↵b Phadia, Uppsala, Sweden.